Physician profile
Ryan W Rogers
NPI 1124325907
$1,001.61
in general payments reported to CMS, 2019-2025
20 companies · $683 in 2025
The $683 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $86.64 · 2022: $152 · 2023: $43.95 · 2024: $35.55 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $679 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $678.58 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $135.62 | 2024-2025 | |
| Janssen Biotech, INC. | $134.62 | 2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $121.56 | 2025 | Entyvio |
| Lilly USA, LLC | $74.26 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $69.30 | 2022-2023 | |
| Madrigal Pharmaceuticals | $67.16 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $58.28 | 2025 | Dupixent |
| Genzyme Corporation | $54.15 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.53 | 2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $31.79 | 2022-2023 | |
| Gilead Sciences, INC. | $30.41 | 2025 | |
| Ardelyx, INC. | $28.68 | 2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $26.61 | 2025 | Zenpep |
| Astrazeneca Pharmaceuticals LP | $25.06 | 2021 | |
| Abbott Laboratories | $18.92 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $17.30 | 2022 | |
| Novo Nordisk INC | $17.16 | 2023 | Wegovy |
| Chiesi USA, INC. | $15.70 | 2021 | |
| Merck Sharp & Dohme LLC | $13.49 | 2021 | |
| Phathom Pharmaceuticals, INC. | $12.01 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.